276 related articles for article (PubMed ID: 17339452)
1. Natural regulation of immunity to minor histocompatibility antigens.
Robertson NJ; Chai JG; Millrain M; Scott D; Hashim F; Manktelow E; Lemonnier F; Simpson E; Dyson J
J Immunol; 2007 Mar; 178(6):3558-65. PubMed ID: 17339452
[TBL] [Abstract][Full Text] [Related]
2. CD8+ but not CD4+ T cells require cognate interactions with target tissues to mediate GVHD across only minor H antigens, whereas both CD4+ and CD8+ T cells require direct leukemic contact to mediate GVL.
Matte-Martone C; Liu J; Jain D; McNiff J; Shlomchik WD
Blood; 2008 Apr; 111(7):3884-92. PubMed ID: 18223170
[TBL] [Abstract][Full Text] [Related]
3. Multicenter analyses demonstrate significant clinical effects of minor histocompatibility antigens on GvHD and GvL after HLA-matched related and unrelated hematopoietic stem cell transplantation.
Spierings E; Kim YH; Hendriks M; Borst E; Sergeant R; Canossi A; Oudshoorn M; Loiseau P; Dolstra H; Markiewicz M; Leffell MS; Pereira N; Kircher B; Turpeinen H; Eliaou JF; Gervais T; Laurin D; Enczmann J; Martinetti M; Thomson J; Oguz F; Santarone S; Partanen J; Siekiera U; Alessandrino EP; Kalayoglu S; Brand R; Goulmy E
Biol Blood Marrow Transplant; 2013 Aug; 19(8):1244-53. PubMed ID: 23756210
[TBL] [Abstract][Full Text] [Related]
4. Expansion of natural killer cell receptor (CD94/NKG2A)-expressing cytolytic CD8 T cells and CD4+CD25+ regulatory T cells from the same cord blood unit.
Tanaka J; Sugita J; Kato N; Toubai T; Ibata M; Shono Y; Ota S; Kondo T; Kobayashi T; Kobayashi M; Asaka M; Imamura M
Exp Hematol; 2007 Oct; 35(10):1562-6. PubMed ID: 17681668
[TBL] [Abstract][Full Text] [Related]
5. Identification of 4 new HLA-DR-restricted minor histocompatibility antigens as hematopoietic targets in antitumor immunity.
Stumpf AN; van der Meijden ED; van Bergen CA; Willemze R; Falkenburg JH; Griffioen M
Blood; 2009 Oct; 114(17):3684-92. PubMed ID: 19706888
[TBL] [Abstract][Full Text] [Related]
6. HA-1H T-Cell Receptor Gene Transfer to Redirect Virus-Specific T Cells for Treatment of Hematological Malignancies After Allogeneic Stem Cell Transplantation: A Phase 1 Clinical Study.
van Balen P; Jedema I; van Loenen MM; de Boer R; van Egmond HM; Hagedoorn RS; Hoogstaten C; Veld SAJ; Hageman L; van Liempt PAG; Zwaginga JJ; Meij P; Veelken H; Falkenburg JHF; Heemskerk MHM
Front Immunol; 2020; 11():1804. PubMed ID: 32973756
[TBL] [Abstract][Full Text] [Related]
7. The non-classical MHC class I molecule Qa-1(b) inhibits classical MHC class I-restricted cytotoxicity of cytotoxic T lymphocytes.
Lohwasser S; Kubota A; Salcedo M; Lian RH; Takei F
Int Immunol; 2001 Mar; 13(3):321-7. PubMed ID: 11222501
[TBL] [Abstract][Full Text] [Related]
8. Collateral damage of nonhematopoietic tissue by hematopoiesis-specific T cells results in graft-versus-host disease during an ongoing profound graft-versus-leukemia reaction.
van der Zouwen B; Kruisselbrink AB; Frederik Falkenburg JH; Jedema I
Biol Blood Marrow Transplant; 2014 Jun; 20(6):760-9. PubMed ID: 24607556
[TBL] [Abstract][Full Text] [Related]
9. Minor histocompatibility antigens--targets of graft versus leukemia responses.
Riddell SR; Murata M; Bryant S; Warren EH
Int J Hematol; 2002 Aug; 76 Suppl 2():155-61. PubMed ID: 12430918
[TBL] [Abstract][Full Text] [Related]
10. Newborn blood used as a source of donor cells in a murine model of transplantation across non-MHC antigens.
de la Selle V; Bruley-Rosset M
Ann N Y Acad Sci; 1995 Dec; 770():351-60. PubMed ID: 8597373
[TBL] [Abstract][Full Text] [Related]
11. Targeting alloreactive donor T-cells to hematopoietic system-restricted minor histocompatibility antigens to dissect graft-versus-leukemia effects from graft-versus-host disease after allogeneic stem cell transplantation.
Mutis T
Int J Hematol; 2003 Oct; 78(3):208-12. PubMed ID: 14604278
[TBL] [Abstract][Full Text] [Related]
12. Memory T cells from minor histocompatibility antigen-vaccinated and virus-immune donors improve GVL and immune reconstitution.
Li N; Matte-Martone C; Zheng H; Cui W; Venkatesan S; Tan HS; McNiff J; Demetris AJ; Roopenian D; Kaech S; Shlomchik WD
Blood; 2011 Nov; 118(22):5965-76. PubMed ID: 21917752
[TBL] [Abstract][Full Text] [Related]
13. Flow cytometric analysis of the graft-versus-Leukemia-effect after hematopoietic stem cell transplantation in mice.
Schmidt F; Hilger N; Oelkrug C; Svanidze E; Ruschpler P; Eichler W; Boldt A; Emmrich F; Fricke S
Cytometry A; 2015 Apr; 87(4):334-45. PubMed ID: 25717029
[TBL] [Abstract][Full Text] [Related]
14. Characterization and manipulation of T cell immunity to skin grafts expressing a transgenic minor antigen.
Valujskikh A; Matesic D; Heeger PS
Transplantation; 1999 Oct; 68(7):1029-36. PubMed ID: 10532546
[TBL] [Abstract][Full Text] [Related]
15. Identification of 4 novel HLA-B*40:01 restricted minor histocompatibility antigens and their potential as targets for graft-versus-leukemia reactivity.
Griffioen M; Honders MW; van der Meijden ED; van Luxemburg-Heijs SA; Lurvink EG; Kester MG; van Bergen CA; Falkenburg JH
Haematologica; 2012 Aug; 97(8):1196-204. PubMed ID: 22419570
[TBL] [Abstract][Full Text] [Related]
16. HY-Specific Induced Regulatory T Cells Display High Specificity and Efficacy in the Prevention of Acute Graft-versus-Host Disease.
Li J; Heinrichs J; Haarberg K; Semple K; Veerapathran A; Liu C; Anasetti C; Yu XZ
J Immunol; 2015 Jul; 195(2):717-25. PubMed ID: 26048147
[TBL] [Abstract][Full Text] [Related]
17. Hematopoietic stem cell recipients do not develop post-transplantation immune tolerance to antigens present on minimal residual disease.
Natzke AM; Shaw JL; McKeller MR; Emo KL; Mullen CA
Biol Blood Marrow Transplant; 2007 Jan; 13(1):34-45. PubMed ID: 17222751
[TBL] [Abstract][Full Text] [Related]
18. Type I-IFNs control GVHD and GVL responses after transplantation.
Robb RJ; Kreijveld E; Kuns RD; Wilson YA; Olver SD; Don AL; Raffelt NC; De Weerd NA; Lineburg KE; Varelias A; Markey KA; Koyama M; Clouston AD; Hertzog PJ; Macdonald KP; Hill GR
Blood; 2011 Sep; 118(12):3399-409. PubMed ID: 21719602
[TBL] [Abstract][Full Text] [Related]
19. Adoptive transfer of allogeneic antigen-specific T cells.
Riddell SR; Bleakley M; Nishida T; Berger C; Warren EH
Biol Blood Marrow Transplant; 2006 Jan; 12(1 Suppl 1):9-12. PubMed ID: 16399578
[TBL] [Abstract][Full Text] [Related]
20. Post-hematopoietic cell transplantation control of graft-versus-host disease by donor CD425 T cells to allow an effective graft-versus-leukemia response.
Jones SC; Murphy GF; Korngold R
Biol Blood Marrow Transplant; 2003 Apr; 9(4):243-56. PubMed ID: 12720217
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
